UPSTREAM BIO INC

UPSTREAM BIO INC’s Nasdaq performance shows sharp volatility—investors track its mid‑cap status, biotech innovations, and market potential for future growth.

Upstream Bio Inc. (UBIO) shows high 52‑week volatility and a $1.62 B market cap, trading above book value with a negative P/E—investors weigh loss‑making prospects and strategic growth.

Upstream Bio’s verekitug, a Phase 2 asthma treatment, makes a strong pitch at the J.P. Morgan Healthcare Conference, hinting at breakthrough prospects for severe respiratory disorders.

Upstream Bio, Inc. is a clinical-stage biotechnology company pioneering a novel approach to treating severe respiratory disorders through its development of verekitug, a unique antagonist targeting the receptor for thymic stromal lymphopoietin (TSLP…

Upstream Bio Inc. is advancing its lead candidate, verekitug, in clinical trials for severe inflammatory diseases, including asthma, chronic rhinosinusitis, and chronic obstructive pulmonary disease.

Upstream Bio Inc, a clinical-stage biotech firm, is navigating financial turbulence while advancing promising treatments for inflammatory diseases, including severe respiratory disorders, through ongoing clinical trials.